{
    "clinical_study": {
        "@rank": "137778", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin type A(Botox\u00ae)", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum toxin type A(Botox\u00ae)"
            }, 
            {
                "arm_group_label": "Botulinum toxin type A(Hugeltox)", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A(Hugeltox)"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy and safety of Hugel-Tox (Botulinum toxin A, Hugel, Korea) against\n      Botox in the treatment of Essential Blepharospasm and to get a regulatory approval from KFDA"
        }, 
        "brief_title": "Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of \"Hugeltox Inj.\" in Essential Blepharospasm", 
        "completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "condition": "Essential Blepharospasm", 
        "condition_browse": {
            "mesh_term": "Blepharospasm"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult between ages 18 and 75 years\n\n          -  All patients, diagnosed of essential blepharospasm, with Grade 2~4 of Severity of\n             Spmasm (by Scott's Method)\n\n        Exclusion Criteria:\n\n          -  Patients have undergone surgical surgery to treat blepharospmasm like myectomy or\n             neurectomy\n\n          -  Patients with hypersensitivity history to botulinum toxin products previously\n\n          -  Patients with secondary blepharomspasm\n\n          -  Patients with hemifacialspasm\n\n          -  Patients with treatment following drugs ; Anticonvulsants, tranquilizers, narcotics,\n             aminoglycoside antibiotics, muscle relaxtants like baclofen etc., blockers of\n             parasympathetic nervous system, levodopa\n\n          -  Patients with previous injection of other botulinum toxin products in 3 months\n\n          -  Patients with any other significant neuromuscular disease like Myasthenia gravis\n\n          -  Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "172", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791881", 
            "org_study_id": "HG-06-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Botulinum toxin type A(Botox\u00ae)", 
                    "Botulinum toxin type A(Hugeltox)"
                ], 
                "description": "1.25U~2.5U/site, Maximum dosage 12.5U~60U/person", 
                "intervention_name": "Hugeltox", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Botulinum toxin type A(Botox\u00ae)", 
                    "Botulinum toxin type A(Hugeltox)"
                ], 
                "description": "1.25U~2.5U/site, Maximum dosage 12.5U~60U/person", 
                "intervention_name": "Botulinum Toxin Type A(Botox\u00ae)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bundang", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Cha Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bundang", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital - Bundang"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Youngnam University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The catholic university, Yeouido, St. Mary's hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The Catholic University, Seoul, St.Mary's hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yeonsei University, Severance hospital - Gangnam"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kim's eye hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chungang University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of \"Hugeltox Inj.\" In Essential Blepharospasm Running Parallel With Phase I Study", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Yoon-Duck Kim, M.D., Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Rate of patients with an improvement more than one Grade of Severity of Spasm (by Scott's Method)", 
            "safety_issue": "Yes", 
            "time_frame": "at 4 weeks post-injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "(1) Duration of action days", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "(2) Grades of Severity of Spasm (by Scott's Method), Functional Visual Status", 
                "safety_issue": "Yes", 
                "time_frame": "at four weeks post-injection"
            }, 
            {
                "measure": "(3) Rate of patients with a Grade-0 or Grade-1 of Severity Spasm (by Scott's Method)", 
                "safety_issue": "Yes", 
                "time_frame": "at four weeks post-injection"
            }, 
            {
                "measure": "(4) Rate of patients with an improvement more than two Grade of Severity of Spasm (by Scott's Method)", 
                "safety_issue": "Yes", 
                "time_frame": "at four weeks post-injection"
            }
        ], 
        "source": "Hugel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hugel", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}